Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

The purpose of the study is to investigate if Tisotumab Vedotin (HuMax®-TF-ADC) is safe and has an additive effect when used with other anti-cancer medications in the treatment of recurrent or advanced cervical cancer.

Patient Profile

Cervical cancer

Where’s this trial being run?

Cork University Hospital, University Hospital Waterford, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: ENGOT-cx8
Number: CTRIAL-IE 18-35
Full Title:

ENGOT-cx8: A Phase 1b/2 Open-label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in combination with other agents in subjects with Recurrent or Stage IVB cervical cancer.

Principal Investigator: Dr Dearbhaile Collins (Cork University Hospital)
Type: Collaborative


Recruitment Started: Global: February 2019
Ireland: May 2019
Global Recruitment Target: 140
Ireland Recruitment Target: 12